Literature Support for Targeted Therapy

Dr. Gerry Post

In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.

Over 20 peer reviewed publications showcase these points.

Here are a few:

Hemangiosarcoma (HSA)

Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma

Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor

Histiocytic Sarcoma

Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib

Targeting MEK in a Translational Model of Histiocytic Sarcoma

Thyroid Carcinoma

Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018)

Transitional Cell Carcinoma (TCC)

Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines

Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.

Pulmonary Adenocarcinoma

Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

Solid Tumors

Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours∗

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Lymphoma

Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma

Apocrine Gland Anal Sac Adenocarcinoma (AGASACA)

Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy. 

© Copyright 2018-2022 OHC, All rights reserved